Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with diabetes, metabolic syndrome, or metabolic dyslipidemia

被引：0
|
作者：
McBride, P
Denke, MA
Pearson, T
Battisti, WP
Brady, WE
Palmisano, J
机构：
[1] Univ Wisconsin, Sch Med, Cardiovasc Dept, Madison, WI USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Kerrville, TX USA
[3] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA
[4] Merck & Co Inc, Clin Dev, West Point, PA USA
来源：
DIABETOLOGIA | 2004年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
559
引用
收藏
页码：A204 / A205
页数：2
相关论文
共 50 条
  • [21] Effectiveness and Safety of Ezetimibe Added to Statin Therapy in Patients with Primary Dyslipidaemia not Achieving the LDL- C Treatment Goal on Statin Monotherapy
    Carlos A. González
    Alberto F. Rubio-Guerra
    Abel Pavía
    Francisco J. Redding
    José L. Cervantes
    José L. Zacarías
    Rubén Yza
    Jaime Carranza
    Pedro Fernández
    Enrique Morales
    Francisco J. Robles
    José L. Leyva
    Leticia Rodríguez
    Clinical Drug Investigation, 2007, 27 : 333 - 337
  • [22] Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy
    Foody, JoAnne M.
    Toth, Peter P.
    Tomassini, Joanne E.
    Sajjan, Shiva
    Ramey, Dena R.
    Neff, David
    Tershakovec, A. Ndrew M.
    Hu, Henry
    Tunceli, Kaan
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 719 - 727
  • [23] Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome.
    Masana, L
    Tonkon, M
    Simons, L
    Lee, M
    Maccubbin, D
    Gumbiner, B
    DIABETOLOGIA, 2003, 46 : A75 - A75
  • [24] Statin Switching: Trends in LDL-C and Predictors of ATP-III Goal Attainment
    Haas, Andrea V.
    Martin-Doyle, William
    Vellanki, Anu
    Carlson, Brigid
    Tighe, Dennis
    CIRCULATION, 2013, 128 (22)
  • [25] Effects of ezetimibe added-to on-going statin therapy on the lipid profile of hypercholesterolemic patients with metabolic syndrome
    Tonkon, M
    Simons, L
    Lee, M
    MacCubbin, D
    Gumbiner, B
    DIABETES, 2003, 52 : A214 - A214
  • [26] LDL-C REDUCTION AND GOAL ACHIEVEMENT IN PATIENTS WITH DIABETES, METABOLIC SYNDROME, OR NEITHER DISEASE, STRATIFIED BY NCEP CHD RISK CATEGORY
    Catapano, A. L.
    Polis, A.
    Abate, N.
    Ballantyne, C. M.
    Davidson, M. H.
    Smugar, S. S.
    Tershakovec, A. M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 73 - 73
  • [27] Enhanced LDL-C lowering and attainment is associated with switches from statin monotherapy to ezetimibe/simvastatin (E/S) therapy
    Toth, P. P.
    Foody, J. M.
    Sajjan, S.
    Ramey, D.
    Neff, D.
    Tershakovec, A. M.
    Hu, H.
    Tomassini, J.
    Tunceli, K.
    EUROPEAN HEART JOURNAL, 2010, 31 : 1022 - 1023
  • [28] Managing the Dyslipidemia of Metabolic Syndrome: Beyond Statin Therapy
    Jialal, Ishwarlal
    Smith, Gerred
    METABOLIC SYNDROME AND RELATED DISORDERS, 2012, 10 (03) : 159 - 160
  • [29] LDL-C goal attainment with the addition of ezetimibe to on-going simvastatin treatment in coronary heart disease patients with hypercholesterolemia
    Brohet, C
    Banai, S
    Alings, AMW
    Massaad, R
    Davies, MJ
    Allen, C
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (04) : 571 - 578
  • [30] RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale
    Inazawa, Takeshi
    Sakamoto, Kentaro
    Kohro, Takahide
    Iijima, Raisuke
    Kitazawa, Toru
    Hirano, Tsutomu
    Kawamura, Mitsunobu
    Tagami, Motoki
    Tanaka, Akira
    Mori, Yasumichi
    Yamazaki, Tsutomu
    Shiba, Teruo
    LIPIDS IN HEALTH AND DISEASE, 2013, 12
12345